Nu-Med Plus Amends Bylaws to Require Shareholder Approval for Domicile Change From Utah
Bitget2026/11/02 21:55- Nu-Med Plus’ board amended its bylaws on November 2, 2026, effective the same day, to clarify shareholder approval requirements.
- Any transfer of domicile or domestication outside Utah requires a majority of votes cast by shares entitled to vote.
- The vote must occur at a meeting with a quorum present, with shares represented in person or by proxy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Crypto prices
More
